Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
Expresses Disappointment with Cephalon
's Rejection of Its Offer
Valeant Pharmaceuticals International
, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has filed with the Securities and Exchange Commission (SEC) a preliminary consent solicitation statement in connection with its solicitation of written consents from the Cephalon
stockholders to remove each member of the Board of Directors of Cephalon
") and elect seven new directors in their place. The proposed directors are:
- Santo J. Costa, Former President and COO of Quintiles
- Richard H. Koppes, Former General Counsel and Interim CEO of CalPERS
- Lawrence N. Kugelman, Former CEO and President of Coventry Health Care
- Anders Lonner, Group President and CEO of Meda
- John H. McArthur, Former Dean of Harvard Business School
- Thomas G. Plaskett, Director of Alcon
- Blair H. Sheppard, Chair and former CEO of Duke Corporate Education and former Dean of Fuqua School of Business, Duke University
formally rejected Valeant's offer. Therefore, Valeant is going directly and immediately to Cephalon
stockholders by initiating its consent solicitation process. It is Valeant's expectation that a new Cephalon
board would act in the best interests of Cephalon
stockholders and remove the impediments to a tender offer, such as the poison pill, and permit Valeant to conduct a due diligence investigation. As stated before, such a due diligence investigation could enable Valeant to modestly increase its offer price, if the results of such investigate demonstrate that additional value exists. In short, Valeant is committed to enabling stockholders to decide whether to accept this offer.
J. Michael Pearson
, Valeant's Chairman and CEO said "In the three weeks since our initial offer, Valeant has recruited seven experienced candidates to serve as director-nominees of Cephalon
. We have arranged financing for our proposed acquisition of Cephalon
. We have received positive feedback from many of the largest stockholders of Cephalon
. We stand ready to quickly commence and close our transaction as proposed, unless Cephalon
stockholders do not support our offer, in which case we will focus our attention on other opportunities to invest our capital. While we are disappointed with the response from Cephalon
's board, we remain committed to our process, which includes trying to find a modest amount of additional value if Cephalon
engages with us and allows us to conduct due diligence, which we believe would take only 2-3 weeks."
Valeant plans to submit a notice with respect to its consent solicitation to Cephalon
's corporate secretary tomorrow morning. Following SEC approval of a definitive consent solicitation statement, Valeant will make the definitive consent solicitation statement available to Cephalon
stockholders and stockholders may begin to deliver their written consents to Valeant's proposals. The Cephalon
board has set April 8 as the record date.
added "We continue to strongly believe that it is in the best interests of both Valeant's and Cephalon
's stockholders to resolve this matter quickly, one way or the other. Valeant will move fast. We had hoped that Cephalon
would do the same. Now, it will be in the stockholders' hands."
CERTAIN INFORMATION CONCERNING POTENTIAL PARTICIPANTS IN A SOLICITATION; ADDITIONAL INFORMATION AND WHERE TO FIND IT
This communication may be deemed to be solicitation material in respect of the proposed removal of directors from, and election of directors to, the Board of Directors of Cephalon
, as well as the repeal of any changes to Cephalon
's Bylaws. On April 5, 2011, Valeant filed a preliminary consent solicitation statement with the SEC. THAT DOCUMENT SETS FORTH THE IDENTITY OF THE PARTICIPANTS IN THE SOLICITATION AND A DESCRIPTION OF THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS, OR OTHERWISE, AND IS AVAILABLE AT THE WEB SITE MAINTAINED BY THE SEC AT . OR FROM VALEANT'S WEBSITE AT UNDER THE TAB "INVESTOR RELATIONS" AND THEN UNDER THE HEADING "SEC FILINGS," OR , FOR FREE, BY DIRECTING A REQUEST TO VALEANT, 7545 IRVINE CENTER DRIVE, CALIFORNIA, 92618, ATTENTION: CORPORATE SECRETARY.
This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. No tender offer for the shares of Cephalon
has commenced at this time.
In connection with any tender offer or consent solicitation, Valeant will file relevant materials, which may include a tender offer statement, and a definitive consent solicitation statement and/or other documents, with the SEC. ALL INVESTORS AND SECURITY HOLDERS OF CEPHALON
ARE URGED TO READ ANY SUCH DOCUMENTS FILED WITH THE SEC BY VALEANT CAREFULLY AND IN THEIR ENTIRETY, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT ANY SUCH TRANSACTION. Investors and security holders will be able to obtain free copies of documents filed with the SEC by Valeant (when they become available) in the same manner as set forth above with respect to the preliminary consent solicitation statement.